In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Righting Wright Medical

Executive Summary

In the early 90's, already strong in total knee replacements, Wright Medical ambitiously staked out markets in hips, trauma, spine and arthroscopy. Much of the expansion was accomplished through a series of acquisitions, perhaps the most important of which was the 1994 acquisition of Orthomet Inc. But those ambitions were never realized, and Wright spent from 1996 to 1998 changing management several times, laying off large numbers of employees and exiting nearly all of the businesses it tried to get into in 1993-'94, all while sales were flat or in decline. Nevertheless, Warburg Pincus, which bought Wright this month, clearly sees opportunity where others don't.

You may also be interested in...



Is Wright Medical Back on Track?

Wright Medical hasn’t enjoyed the smoothest ride over the past 15 years, a stretch that included a spin-out, debt problems, and a buyout, as well as an IPO. All the while, though, the company has proven to be an innovator in the large joints industries and now—under new CEO Gary Henley—it is establishing itself as a force in the extremities and biomaterials markets.

Is Wright Medical Back on Track?

Wright Medical hasn’t enjoyed the smoothest ride over the past 15 years, a stretch that included a spin-out, debt problems, and a buyout, as well as an IPO. All the while, though, the company has proven to be an innovator in the large joints industries and now—under new CEO Gary Henley—it is establishing itself as a force in the extremities and biomaterials markets.

Devices Pique Private Equity's Interest

The spate of recent carve-outs from Boston Scientific has private equity and venture capital investors hungry for similar deals across the industry. But device companies don't seem to be serving much up.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel